The BACH1 Knockout HT29 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal population of HT29 cells with targeted disruption of the BACH1 gene. This loss-of-function model enables researchers to dissect the transcriptional repressor roles of BACH1 in colorectal adenocarcinoma cells. The polyclonal knockout cells provide a heterogeneous gene-disrupted population suitable for functional studies without the constraints of single-cell clonal selection.
The HT29 cell line is a widely used human colorectal adenocarcinoma model originally derived from a female patient. These adherent epithelial cells harbor oncogenic mutations including APC truncation, BRAF V600E, and mutant TP53, which recapitulate key genetic drivers of colorectal cancer. HT29 cells exhibit a moderate differentiation phenotype and are extensively employed in studies of intestinal epithelial biology, drug response, and metastasis.
BACH1 functions as a transcriptional repressor that directly competes with NRF2 for binding to antioxidant response elements (ARE) in the promoters of target genes. Under homeostatic conditions, BACH1 forms heterodimers with small Maf proteins (MAFF, MAFG, MAFK) and occupies ARE sequences, thereby repressing transcription of cytoprotective enzymes such as heme oxygenase-1 (HMOX1) and NAD(P)H quinone dehydrogenase 1 (NQO1). The repressive activity of BACH1 is antagonized by oxidative stress and elevated intracellular heme, which promote BACH1 nuclear export or FBXO22-mediated proteasomal degradation, enabling NRF2-dependent transcriptional activation. BACH1 also integrates signals from MAPK cascades and has been implicated in the regulation of genes involved in ferroptosis, cellular senescence, Wnt/??-catenin signaling, and metastasis, including matrix metalloproteinases (MMPs) and the chemokine receptor CXCR4.
In the HT29 colorectal adenocarcinoma background, disruption of BACH1 is particularly informative for exploring the interplay between oncogenic signaling and redox homeostasis. HT29 cells exhibit constitutively active Wnt/??-catenin signaling due to APC mutation and MAPK pathway activation driven by BRAF V600E, both of which intersect with BACH1 regulatory functions. Ablation of BACH1 in this context is expected to derepress NRF2 target genes, potentially enhancing antioxidant defenses and conferring resistance to oxidative damage, while simultaneously modulating ferroptosis sensitivity and invasive behavior. Consequently, the BACH1 Knockout HT29 Polyclonal Cells serve as a powerful tool for dissecting how transcriptional repression by BACH1 influences malignant phenotypes in colorectal cancer.
Researchers can employ these BACH1 knockout cells in a variety of experimental paradigms, including assessing changes in ROS levels upon ferroptosis induction, quantifying antioxidant gene expression via RT-qPCR, and performing chromatin immunoprecipitation to examine NRF2 and small Maf protein occupancy at AREs. Migration and invasion assays combined with RNA-seq analysis provide insight into BACH1-dependent metastatic programs. Additionally, drug sensitivity profiling can reveal how loss of BACH1 affects responses to chemotherapeutics or targeted agents. For further inquiries, please contact Ascent Research.
